Murine Polyomavirus Virus-Like Particles Carrying Full-Length Human PSA Protect BALB/c Mice from Outgrowth of a PSA Expressing Tumor
2011

Using Virus-Like Particles to Protect Mice from Prostate Cancer

Sample size: 70 publication 10 minutes Evidence: moderate

Author Information

Author(s): Mathilda Eriksson, Kalle Andreasson, Joachim Weidmann, Kajsa Lundberg, Karin Tegerstedt, Tina Dalianis, Torbjörn Ramqvist

Primary Institution: Karolinska Institutet, Stockholm, Sweden

Hypothesis

Can murine polyomavirus virus-like particles carrying human prostate specific antigen protect mice from tumor outgrowth?

Conclusion

Immunization with PSA-MPyVLPs loaded onto dendritic cells and co-injected with CpG induces an efficient immune response against PSA, protecting mice from tumor outgrowth.

Supporting Evidence

  • Immunization with PSA-MPyVLPs alone resulted in a 50% tumor take compared to 79% in non-immunized mice.
  • Co-injection of PSA-MPyVLPs and CpG resulted in a protective effect with a 46% tumor take.
  • Loading of PSA-MPyVLPs onto dendritic cells and co-injecting with CpG reduced the tumor take to 15%.

Takeaway

Researchers created a vaccine using virus-like particles to help mice fight prostate cancer, and it worked better when combined with special immune cells.

Methodology

BALB/c mice were immunized with PSA-MPyVLPs, either alone or loaded onto dendritic cells, and co-injected with CpG adjuvant, followed by tumor cell challenge.

Limitations

The study was conducted in a mouse model, which may not fully replicate human responses.

Participant Demographics

Female BALB/c mice, aged 6–10 weeks.

Statistical Information

P-Value

<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1371/journal.pone.0023828

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication